Background: A key task for the pharmaceutical industry is to understand the compliance implications of engaging with a patient advocacy group (PAG). This presents challenges for the industry to negotiate the ethical and reputational issues that can arise when working with a PAG. Objective: To gain the views of pharmaceutical industry executives on future compliance challenges when working with PAGs. Study design: We conducted two surveys among two sets of industry executives: one group focussed on market access roles and the other focussed on non-market access roles. Results: Transparency was identified as the biggest challenge, followed by project rationale and then by project ownership. Conclusion: We explore how this can be overcome and make recommendations on how best to work compliantly with PAGs.
T he pharmaceutical industry endeavours to understand patient experiences and address unmet patient needs by engaging with patient advocacy groups (PAGs). However, this raises important compliance, ethical and reputational considerations.
Compliance encompasses the endeavours of pharmaceutical companies to conform to relevant legislation and code of practice governing advertising, communications and interactions with customers. These have been described in a recent review (1) .
In the United Kingdom, code of practice breaches are governed by the Association of the British Pharmaceutical Industry (2) . Additional guidelines usually apply in the member countries of the International Federation of Pharmaceutical Manufacturers and Associations (3), which also issues universal minimum standards wherever international companies operate Á even if there is no effective local regulatory framework.
This article reviews two online surveys of pharmaceutical industry executives on the compliance challenges when working with PAGs as part of a market access programme during Phase III. From these results, we present a five-part model for successfully working with a PAG in a sustainable and ethically compliant manner. To the best of our knowledge, this is the first practical discussion to make recommendations on this subject.
Method Methodology
Two online surveys were conducted in December 2015 and January 2016. The first group included 35 pharmaceutical executives with varying geographical responsibility (Table 1 ) involved in non-market access functions (Tables 2  and 3 ). The second group comprised 18 executives, primarily responsible for market access ( Table 2 ). The aim was to evaluate the groups' understanding of the compliance considerations (Table 4 ) and challenges (Table 5) facing a pharmaceutical company when partnering with PAGs over the next 5 years.
Results
Transparency was seen as the most important common consideration for a compliant partnership (Table 6 ), followed by project rationale and then by project ownership (Table 7) . The additional areas raised in the survey are listed in Table 8 .
Involvement of PAGs in health technology assessment (HTA) was the most significant compliance challenge in the next 5 years, followed by appropriate level of PAG funding and then shared access to research data (Table 9) .
There was a difference between the two groups about the most important compliance challenge (Table 10 ). The wider group gave almost equal importance to appropriate funding of patient groups and involvement in HTA. Those working primarily in market access identified the involvement of PAGs in HTA as the priority challenge, followed by shared access to research data, with correct funding of PAGs ranked third.
Discussion

Research limitations
The principal limitations were small survey size and the multiple roles of respondents. The questions were developed with senior compliance executives, yet the possibility of response bias from question phrasing remains.
Transparency
The approaches to compliance fall into two broad types: a legally driven approach and those founded on wellrespected codes of practice. Both laws and codes exist in all developed countries, but the balance between the two can be very different. Compliance and ethics experts should be an integral part of the team developing advocacy strategy. Ideally, executives who interact with PAGs should hold a noncommercial function, such as medical affairs or advocacy.
In disease areas where there are no PAGs, or where few pharmaceutical companies are operating, companies should beware of being a single or dominant sponsor, since this creates questions over independence. The European Federation of Pharmaceutical Industries and Associations (EFPIA) code prohibits this (4).
In emerging markets, PAGs are generally not well developed and some may not have worked with companies. Also, local teams may not be applying the same standards as international companies, and the local culture can be very different from developed countries. Work by Transparency International identifies countries with a high corruption index and can help ethical compliant relationships worldwide (5) . International companies should have internal standards that ensure similar compliance and ethics requirements wherever they operate.
Best practice compliance details a company's engagement with a PAG, ideally over a number of years with an obvious research and development strategy, rather than a sales-motivated relationship, and will also include extensive record-keeping and documentation.
Project rationale
A defined project rationale is essential to create a trustbased PAG partnership. Every interaction with a patient group should have a clearly defined legal contract which sets out why a company is working with a patient group, and what each party will gain from the partnership and in what timescale. This avoids the risk of hidden promotion.
Creating a clear rationale involves understanding the key players and their interactions, and creating an understanding in the company of a PAG's needs and perspectives. However, agreeing on a rationale means accepting and understanding the long-term nature of patient engagement. This cannot be captured in conventional sales metrics; yet there is equity value in building partnerships, which cannot be measured by traditional means. Understanding the key influencers' interactions shape the advocacy strategy. Thorough analysis of each advocacy group's priorities, policies and positions provides insight into the issues that matter to patients. Advocacy objectives, and therefore a project's rationale, will be different when a company creates a new partnership, compared with an established institutional presence. For example, the emphasis in a new partnership will be on understanding unmet needs and creating a mutual agenda.
Patient group ownership
As patients are increasingly well-informed, organised and powerful, more and more companies are prioritising patient-centrism. This means integrating patient inputs in each stage of the value chain, from drug development through to commercialisation and lifecycle management. Early engagement during development Á in some ways Á poses fewer compliance issues, as no drug has been launched. Involvement well before the availability of a drug avoids the perception of a purely commercial interest and shows a commitment to long-term partnering with PAGs.
One of the main reasons for losing trust is companies reaching out to a PAG before there is internal clarity on what a company wants to achieve. Often, these activities are not thought through in sufficient detail in the early stages of the planning process, leading to a mismatch of shared aims.
HTA involvement
The difference between the two groups' views on the most significant compliance challenge illustrates an important consideration when planning an advocacy strategy; the need to think beyond partnering just for access and instead addressing unmet needs of the PAG (6, 7).
The market access executives saw the PAGs as having mainly an HTA role, whereas sustainable partnering is likely to involve working on common aims which may or may not be related to access. This was also recognised by the other responders. Internally, advocacy must therefore align with other members of the global access team to scope out priorities. How this is done depends on the way the advocacy function is built into the company infrastructure and the corporate compliance culture, and there must be a transparent, legitimate and responsible communication with patient groups, which acknowledge the sources of funding.
PAG funding
This represents an advocacy opportunity to address unmet patient needs and a compliance challenge Á especially if there are few companies in the area. Many PAGs rely on pharmaceutical funding, either as unrestricted medical grants or project funding provided for a specific activity, which must be declared by the pharmaceutical company.
Withdrawal of funding can present a PAG with a funding crisis. This is where early transparency, and a clearly defined, detailed, agreed contract, can minimise the risk of reputational damage.
Conclusions
Pharmaceutical company interactions with PAGs must be highly regulated and transparent to avoid the riskof damage to reputation that ensues if companies fail to observe the rules and regulations set out to ensure compliance. The transparency must reinforce the legitimacy of the partnership.
This article provides a useful first step in identifying and planning how to find common points of interest to work together, by focusing on the key compliance challenges now and in the immediate future, and their solutions.
While the results need to be interpreted with caution, they provide useful insights and provoke debate on successful compliant advocacy strategy at the time of Phase III.
